Zobrazeno 1 - 10
of 169
pro vyhledávání: '"F Calabresi"'
OBJECTIVE: To measure the global impact of COVID-19 pandemic on volumes of IV thrombolysis (IVT), IVT transfers, and stroke hospitalizations over 4 months at the height of the pandemic (March 1 to June 30, 2020) compared with 2 control 4-month period
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______2127::2ed670180d644af21926571cb91851d3
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3102266
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3102266
Autor:
M. De Rosa, C. Besana, Francesco Boccardo, A. Lucenti, Giovanni Citterio, Enzo Galligioni, Roberto Sorio, Luciano Canobbio, G. Landonio, Enzo Maria Ruggeri, Francesco Cognetti, C. Baiocchi, F. Calabresi, Alessandra Rubagotti
Publikováno v:
Tumori Journal. 84:534-539
Background The purpose of the present study was to investigate the therapeutic effectiveness of interleukin-2 (IL-2) and interferon (IFN), either alone or in combination, in comparable groups of patients affected by advanced renal cell carcinoma (RCC
Autor:
J. Latreille, J.M. Ford, J Bonneterre, Pierfranco Conte, G Francini, F. Calabresi, D. M. B. Campos, R Santos, L. Mauriac
Publikováno v:
Journal of Clinical Oncology. 14:2552-2559
PURPOSE Bone metastases are a major cause of morbidity in breast cancer, resulting in complications that include pain, loss of mobility, pathologic fracture, and tumor-induced hypercalcemia (TIH). Inhibition of osteoclast-mediated bone destruction us
Autor:
V De Sanctis, Mauro Fiacchini, Pier Luigi Zinzani, Tura S, Maria Paola Martelli, Marco Vignetti, Giovanna Meloni, F Calabresi, M F Martelli, Franco Gherlinzoni, Franco Mandelli, Giuseppe Papa
Publikováno v:
Journal of Clinical Oncology. 14:534-542
PURPOSE To evaluate, in a prospective multicentric study, the efficacy of a conventional salvage chemotherapy (dexamethasone, cisplatin, and cytarabine [DHAP]) versus high-dose chemotherapy (carmustine, etoposide, cytarabine, and cyclophosphamide [BE
Autor:
Igea D'Agnano, Cora N. Sternberg, F. Calabresi, M. G. Arena, P. De Carli, M. Zeuli, A. Cancrini, F. Rosenkaimer, Gabriella Zupi, Vito Pansadoro
Publikováno v:
Europe PubMed Central
Twenty patients with histologically documented superficial bladder cancer (Ta, T1, Tis) were treated with intravesical administration of TNF 400-1800 micrograms. Of 18 patients with a marker lesion, 2 obtained a complete response for 8+ and 18 months
Autor:
R. Bartolucci, M. Sofra, Virginio Belsanti, M. Marzola, Corrado Boni, F. Calabresi, F. Di Costanzo, M. Bacchi
Publikováno v:
Annals of Oncology. 3:371-376
One hundred eighty-one patients with measurable recurrent or metastatic colorectal cancer, who had not received prior chemotherapy, were randomized in a prospective controlled trial to receive 5-fluorouracil (5FU), 13.5 mg/kg, for five days (arm A) o
Publikováno v:
American Journal of Clinical Oncology. 20:230-232
The response rate to salvage chemotherapy in advanced ovarian cancer has been disappointing in patients who do not respond or who relapse after platinum-containing regimens. In these cases, the identification of new drugs is a substantial challenge.
Autor:
B. Osterwalder, Wim H. J. Kruit, S. H. Goey, H. Poliwoda, F. Calabresi, G. Stoter, A. Lindemann, Rolf A. Stahel
Publikováno v:
British Journal of Cancer
Fifty-seven patients with metastatic melanoma were treated with interleukin 2 (IL-2) 7.8 MIU m-2 day-1 as a continuous infusion for 4 days combined with interferon alpha (IFN-alpha) 6 MIU m-2 day-1 subcutaneously on days 1 and 4. The cycle was repeat
Autor:
LM Rossi-Ferragut, CC Rocha, A laconelli Jr, T Aoki, ARC Medeiros, F Calabresi, WCP Busato, E Borges Jr
Publikováno v:
JBRA Assisted Reproduction. 5
Autor:
R. L. H. Bolhuis, S. H. Goey, J. R. T. Monson, Rolf A. Stahel, Gerrit Stoter, P. H. M. Mulder, Wim H. J. Kruit, F. Calabresi, A. M. M. Eggermont, RH Mertelsmann, E. E. Holdener
Publikováno v:
British Journal of Haematology. 79:84-86
A multicentre study of IL2 and IFN alpha has been performed in 58 patients with metastatic melanoma. The scheme consisted of IL2 3.0 BRMP MU/m2/d as a continuous infusion for 4 d combined with subcutaneous administration of IFN alpha 6 MU/m2/d, day 1